HDAC6 and colitis: It has been shown that the administration of HDACi to mice leads to a decrease in intestinal inflammation as a result of acetylation of FOXP3.67 In 2011, De Zoeten et al68 showed that Tubacin, which is a selective HDAC6 inhibitor, inhibited intestinal inflammation in a DSS-induced colitis model through its effect on FOXP3+ Treg cells.